Declaration of competing financial interests
From the following article:
Martin O Savage, Kenneth M Attie, Alessia David, Louise A Metherell, Adrian JL Clark & Cecilia Camacho-Hübner
Nature Clinical Practice Endocrinology & Metabolism 2, 395-407 (July 2006)
doi:10.1038/ncpendmet0195
Declaration: Martin O Savage is an Investigator in a Phase III study on effects of rhIGF–rhIGFBP3 (recombinant human insulin-like growth factor 1–rhIGF binding protein 3) treatment in growth-hormone-insensitivity syndrome organized by Insmed Inc., Glen Allen, VA, USA.
Keneth M Attie is Vice President Medical Affairs at Insmed Inc., Glen Allen, VA, USA. This company is organizing a Phase III study of rhIGF1–rhIGFBP3 (recombinant human insulin-like growth factor 1–rhIGF binding protein 3) treatment of growth-hormone-insensitivity syndrome.
Cecilia Camacho-Hübner is a Principal Investigator in a Phase III study on effects of rhIGF1–rhIGFBP3 (recombinant human insulin-like growth factor 1–rhIGF binding protein 3) treatment in growth-hormone-insensitivity syndrome organized by Insmed Inc., Glen Allen, VA, USA.
